---
title: "Shandong Boan Biotechnology Transfers 38.5 Million H Shares to New Investor"
description: "Shandong Boan Biotechnology Co. Ltd. announced that its controlling shareholder, Luye Pharma Group Ltd., will transfer 38.5 million H Shares to the Issuer on January 22, 2026. This transfer is part of"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273242243.md"
published_at: "2026-01-21T14:06:08.000Z"
---

# Shandong Boan Biotechnology Transfers 38.5 Million H Shares to New Investor

> Shandong Boan Biotechnology Co. Ltd. announced that its controlling shareholder, Luye Pharma Group Ltd., will transfer 38.5 million H Shares to the Issuer on January 22, 2026. This transfer is part of a subscription agreement related to Exchangeable Preference Shares. The board expects no material adverse effect on the company's operations from this transaction.

Shandong Boan Biotechnology Co. Ltd. announced that its controlling shareholder, Luye Pharma Group Ltd., through its wholly-owned subsidiary Shandong Luye Pharmaceutical Co., Ltd., will transfer 38,500,000 H Shares of Shandong Boan Biotechnology to the Issuer on January 22, 2026. This transfer is part of a previously disclosed arrangement under a subscription agreement related to Exchangeable Preference Shares. The board of Shandong Boan Biotechnology does not expect the transaction to have any material adverse effect on the company’s business operations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260121-11997569), on January 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [560600.CN - Founder Fubon CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/560600.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [06955.HK - BOAN BIOTECH](https://longbridge.com/en/quote/06955.HK.md)
- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hangzhou Jiuyuan’s Semaglutide Biosimilar Jikeqin Advances Toward China Market Approval | Hangzhou Jiuyuan Gene Engineering Co Ltd has developed Jikeqin, a biosimilar of semaglutide for weight management. The d | [Link](https://longbridge.com/en/news/276936312.md) |
| HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China | HBM Holdings (SEHK:2142) has entered an exclusive partnership with Solstice Oncology for its clinical asset HBM4003 outs | [Link](https://longbridge.com/en/news/276700073.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |
| China's Jiuyuan Genetic seeks approval for Wegovy biosimilar | Jiuyuan Genetic Biopharmaceutical has applied for approval to sell its biosimilar version of Wegovy in China, ahead of a | [Link](https://longbridge.com/en/news/276994337.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/en/news/276718382.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.